Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL).Narendranath Epperla, Timothy S. Fenske, Kwang Woo Ahn et al.|Journal of Clinical Oncology|2016Cited by 0